NBIX
Income statement / Annual
Last year (2023), Neurocrine Biosciences, Inc.'s total revenue was $1.89 B,
an increase of 26.76% from the previous year.
In 2023, Neurocrine Biosciences, Inc.'s net income was $249.70 M.
See Neurocrine Biosciences, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$1.89 B
|
$1.49 B
|
$1.13 B
|
$1.05 B
|
$788.10 M
|
$451.24 M
|
$161.63 M
|
$15.00 M
|
$19.77 M
|
$0.00
|
| Cost of Revenue |
$39.70 M |
$23.20 M |
$14.30 M |
$10.10 M |
$7.40 M |
$4.89 M |
$1.25 M |
$35.90 M |
$33.80 M |
$14.40 M |
| Gross Profit |
$1.85 B |
$1.47 B |
$1.12 B |
$1.04 B |
$780.70 M |
$446.35 M |
$160.37 M |
-$20.90 M |
-$14.03 M |
-$14.40 M |
| Gross Profit Ratio |
0.98 |
0.98 |
0.99 |
0.99 |
0.99 |
0.99 |
0.99 |
-1.39 |
-0.71 |
0 |
| Research and Development
Expenses |
$565.00 M
|
$463.80 M
|
$328.10 M
|
$275.00 M
|
$200.00 M
|
$160.52 M
|
$121.83 M
|
$94.29 M
|
$81.49 M
|
$46.43 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$248.93 M
|
$169.91 M
|
$68.08 M
|
$32.48 M
|
$17.99 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$887.60 M
|
$752.70 M
|
$583.30 M
|
$433.30 M
|
$354.10 M
|
$248.93 M
|
$169.91 M
|
$68.08 M
|
$32.48 M
|
$17.99 M
|
| Other Expenses |
$143.90 M |
$0.00 |
$105.30 M |
$164.50 M |
$154.27 M |
$0.00 |
-$20,000.00 |
$13,000.00 |
$11,000.00 |
$18,000.00 |
| Operating Expenses |
$1.60 B |
$1.22 B |
$911.40 M |
$708.30 M |
$554.10 M |
$409.46 M |
$291.73 M |
$162.37 M |
$113.97 M |
$64.41 M |
| Cost And Expenses |
$1.64 B |
$1.24 B |
$925.70 M |
$718.40 M |
$561.50 M |
$414.35 M |
$292.99 M |
$162.37 M |
$113.97 M |
$64.41 M |
| Interest Income |
$0.00 |
$11.20 M |
$3.80 M |
$12.60 M |
$19.21 M |
$0.00 |
$0.00 |
$2.84 M |
$1.93 M |
$629,000.00 |
| Interest Expense |
$4.60 M |
$7.10 M |
$25.80 M |
$32.80 M |
$32.00 M |
$30.53 M |
$19.52 M |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$21.30 M
|
$15.60 M
|
$10.90 M
|
$8.60 M
|
$7.45 M
|
$4.02 M
|
$2.40 M
|
$1.50 M
|
$1.01 M
|
$827,000.00
|
| EBITDA |
$416.10 M
|
$264.60 M
|
$218.70 M
|
$336.10 M
|
$226.60 M
|
$56.40 M
|
-$120.62 M
|
-$139.59 M
|
-$87.92 M
|
-$63.58 M
|
| EBITDA Ratio |
0.22 |
0.17 |
0.18 |
0.31 |
0.29 |
0.08 |
-0.81 |
-10.24 |
-5.03 |
0 |
| Operating Income Ratio
|
0.13
|
0.17
|
0.17
|
0.3
|
0.28
|
0.08
|
-0.81
|
-9.82
|
-4.77
|
0
|
| Total Other
Income/Expenses Net |
$81.20 M
|
-$35.10 M
|
-$1.10 M
|
-$56.30 M
|
-$25.80 M
|
-$15.05 M
|
-$11.18 M
|
$6.28 M
|
$5.27 M
|
$3.87 M
|
| Income Before Tax |
$332.10 M |
$213.90 M |
$101.40 M |
$106.70 M |
$46.50 M |
$21.84 M |
-$142.54 M |
-$141.09 M |
-$88.93 M |
-$60.54 M |
| Income Before Tax Ratio
|
0.18
|
0.14
|
0.09
|
0.1
|
0.06
|
0.05
|
-0.88
|
-9.41
|
-4.5
|
0
|
| Income Tax Expense |
$82.40 M |
$59.40 M |
$11.80 M |
-$300.60 M |
$9.50 M |
$730,000.00 |
$17.10 M |
-$7.72 M |
-$6.27 M |
-$4.68 M |
| Net Income |
$249.70 M |
$154.50 M |
$89.60 M |
$407.30 M |
$37.00 M |
$21.11 M |
-$142.54 M |
-$141.09 M |
-$88.93 M |
-$60.54 M |
| Net Income Ratio |
0.13 |
0.1 |
0.08 |
0.39 |
0.05 |
0.05 |
-0.88 |
-9.41 |
-4.5 |
0 |
| EPS |
2.56 |
1.61 |
0.95 |
4.37 |
0.4 |
0.22 |
-1.62 |
-1.63 |
-1.05 |
-0.81 |
| EPS Diluted |
2.47 |
1.56 |
0.92 |
4.16 |
0.39 |
0.22 |
-1.62 |
-1.63 |
-1.05 |
-0.81 |
| Weighted Average Shares
Out |
$97.70 M
|
$95.80 M
|
$94.60 M
|
$93.10 M
|
$91.63 M
|
$95.40 M
|
$87.99 M
|
$86.56 M
|
$84.50 M
|
$74.58 M
|
| Weighted Average Shares
Out Diluted |
$101.00 M
|
$98.90 M
|
$97.90 M
|
$97.80 M
|
$95.73 M
|
$95.40 M
|
$88.09 M
|
$86.71 M
|
$84.50 M
|
$74.58 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
